Roger is a Senior Advisor on the Frazier Life Sciences team, and brings several decades of both leadership and operational experience within the pharmaceutical industry.
Roger joined Frazier Healthcare Partners' Life Sciences team in 2016 as a Senior Advisor, and has worked with Frazier-backed portfolio companies for over 10 years. He was with Acerta Pharma as both a member of the company’s founding Board of Directors and as Chief Scientific Officer through its majority-share acquisition by AstraZeneca (total consideration of up to $7 billion). Acerta/AstraZeneca are developing acalabrutinib, a second-generation BTK inhibitor, for the treatment of patients with hematological malignancies. He was previously co-founder and Chief Development Officer with Calistoga Pharmaceuticals, a Frazier portfolio company, and guided the development of CAL-101 (GS1101, idelalisib), an isoform-selective PI3K inhibitor. Calistoga was acquired by Gilead Sciences, and Roger continued with Gilead to help with the Calistoga integration and complete the development of CAL-101, now marketed as Zydelig.
Prior to Calistoga, he was Senior Scientific Director with Merck Research Laboratories, where he helped guide the Merck integration of Seattle-based Rosetta Inpharmatics. Prior to Merck, he was Director of Drug Safety Evaluation at Abbott Laboratories, and was Senior Scientist with both The Upjohn Company and Pharmacia & Upjohn Inc. Having participated on many project teams across therapeutic areas, he understands why drugs fail and what it takes to succeed. Roger directly contributed to the discovery, development, approval, and life cycle of several products, including Zydelig, Camptosar, Zyvox, Spexil, Colestid Tablets, Actos, Kaletra and Humira. Prior to his career in the pharmaceutical industry, he held research positions at West Virginia and Michigan State Universities, and at Argonne National Laboratories. He currently serves on the boards of Acerta Pharma, Remedy Pharmaceuticals, and Aminex, and serves as a scientific advisor to several small companies, including Frazier portfolio company Millendo Therapeutics (formerly Atterocor).
Roger received his Ph.D. in Cellular and Molecular Biology from West Virginia University, where he studied the role of protein kinases and cytoskeletal function in cancer. He holds several patents, has authored more than 120 publications, and is a Fellow of the Academy of Toxicological Sciences.
Ph.D., West Virginia University